MedTrace Logo

A Clinical Trial to Compare the Safety and Pharmacokinetic Characteristics of Combination of Rosuvastatin and CS-866 and DWJ1276

NCT01493856 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2012-04-04

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and pharmacokinetic characteristics of combination of rosuvastatin and CS-866 and DWJ1276 alone.

Conditions

  • Healthy Volunteers

Interventions

DRUG

Cresto

tablet, rosuvastatin 20mg

DRUG

Olmetec

tablet, olmesartan medoxomil(CS-866) 40mg

DRUG

DWJ1276

tablet, Rosuvastatin 20mg and olmesartan medoxomil 40mg

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Principal Investigators

  • Kyungsoo Park, M.D., Ph.D. · YONSEI UNIVERSITY HEALTH SYSTEM (YUHS)

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2012-02-29
Completion
2012-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01493856 on ClinicalTrials.gov